Testing picankibart for active psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have had psoriatic arthritis for at least 3 months
- You have at least 3 tender joints and 3 swollen joints currently
- You have active plaque psoriasis (at least one patch 2 cm or larger), nail psoriasis, or a past history of plaque psoriasis
- You have tried NSAIDs or non-biologic DMARDs and they did not work well enough or caused side effects
- You have not used more than 2 biologic drugs before and are not on any prohibited medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tulisokibart for people with psoriatic arthritis (PsA), a condition that causes joint pain and skin plaques. It may help if you have not tried certain biologic medications or if they did not work well.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This trial tests an experimental oral medication called TQH3906 for people with active psoriatic arthritis (PsA), a condition that causes joint pain, swelling, and skin psoriasis. The study aims to see if TQH3906 is safe and effective in reducing arthritis symptoms.
This study compares two “treat-to-target” strategies for psoriatic arthritis. One strategy uses imaging to guide treatment changes, and the other uses standard clinic assessments, to see which approach controls symptoms more effectively.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
This trial tests a new medication called icotrokinra for people with active psoriatic arthritis (PsA). It aims to see how well the drug works and if it is safe, including for those who have tried other treatments.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.